Type 2 Diabetes Trial, Not Yet Recruiting NCT07570667 Sponsor: The University of Hong Kong Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Not Yet Recruiting

NCT07570667
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have signed the study's consent form.
  • Men or women are eligible to participate.
  • People aged between 40 and 70 years old at the first visit.
  • For the Low-risk group: People who are generally healthy, free from ongoing or long-term illness, and who do not have the cardiovascular risk conditions listed in the fifth inclusion criterion — minor health issues that do not need regular medication are acceptable. For the High-risk group: People who are generally healthy but do have the cardiovascular risk conditions listed in the fifth inclusion criterion — minor health issues that do not need regular medication are acceptable.
  • For the Low-risk group: People with a low risk of developing a non-communicable disease (such as heart disease or cancer) in the coming years, meaning they have never been treated for high blood pressure, have total cholesterol below 5.2 mmol/L with no history of cholesterol-lowering medication, and are non-smokers or have very minimal smoking history (fewer than 5 pack-years). For the High-risk group: People with a high risk of developing a non-communicable disease, confirmed by having at least 2 of the following 3 conditions — (a) diagnosed high blood pressure currently managed with medication; (b) diagnosed high cholesterol or abnormal blood fats currently managed with medication; (c) a significant smoking history (more than 20 pack-years) and/or a parent, sibling, or child with a history of lung cancer.
  • People with a body mass index (BMI) between 18.5 and 35.0 kg/m².
  • People who are willing to complete study questionnaires.
  • People who are willing to attend future study visits and medical tests as required by the study plan.
  • People who agree to have their health outcomes tracked through linkage to their existing health records.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are pregnant at the time of the first visit (based on self-report — no test is required).
  • For the Low-risk group: People who have a past or current history of the diseases this study is targeting, any other significant health conditions, symptoms, or abnormal test results suggesting a health problem at the first visit, or any condition that is not well managed. For the High-risk group: Aside from the high blood pressure and cholesterol conditions listed as qualifying criteria, people with a history of the diseases this study is targeting, other significant health conditions, symptoms, or abnormal test results at the first visit, or any condition that is not well managed.
  • For the Low-risk group: People who are currently taking any ongoing prescription medication that works throughout the whole body. For the High-risk group: People who are currently taking any ongoing prescription medication that works throughout the whole body, except for the blood pressure or cholesterol medications that qualify them for the High-risk group.
  • People with a history of HIV, Hepatitis B, Hepatitis C, or Hepatitis E infection at the first visit.
  • People considered to be vulnerable participants (confirm with trial site).
  • People who are unlikely to be able to follow the study requirements as planned.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dennis KM Ip, MD, School of Public Health, The University of Hong Kong

Phone: (+852) 39176714

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
29 May 2048

Where this trial is recruiting

Hong Kong

Primary endpoints

Establish Personalized Molecular Baselines; Establishment of Health Screening Algorithm; Identification of molecular signatures

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov